Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 42, 2012, Pages 16906-16910

  Vogel, Simon M ^a,b   Bauer, Matthias R ^a,b   Joerger, Andreas C ^b   Wilcken, Rainer ^a,b   Brandt, Tobias ^b   Veprintsev, Dmitry B ^b,c   Rutherford, Trevor J ^b   Fersht, Alan R ^b   Boeckler, Frank M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

Bile acid sensor; Cancer pathways; HDMX; Natural product; Virtual screening

Indexed keywords

CASPASE 3; CASPASE 7; E1A ASSOCIATED P300 PROTEIN; LIGAND; LITHOCHOLIC ACID; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

APOPTOSIS; ARTICLE; BINDING SITE; CARCINOGENIC ACTIVITY; CELL STRAIN HCT116; COMPUTER MODEL; DISSOCIATION CONSTANT; ENZYME INDUCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TRANSCRIPTION INITIATION; UPREGULATION;

APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; ESCHERICHIA COLI; FLUORESCENCE POLARIZATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LITHOCHOLIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; ULTRACENTRIFUGATION;

EID: 84867649020     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1215060109     Document Type: Article

References (39)

1. Vousden KH, Prives C (2009) Blinded by the light: The growing complexity of p53. Cell 137:413-431.
2. Joerger AC, Fersht AR (2008) Structural biology of the tumor suppressor p53. Annu Rev Biochem 77:557-582.
3. Toledo F, Wahl GM (2006) Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909- 923.
4. Popowicz GM, Czarna A, Holak TA (2008) Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 7:2441-2443.
5. Kussie PH, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-953. (Pubitemid 26398409)
6. Boeckler FM, et al. (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105:10360-10365.
7. Toledo F, Wahl GM (2007) MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 39:1476-1482. (Pubitemid 47031042)
8. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: Drugging the p53 pathway. Nat Rev Cancer 9:862-873.
9. WadeM, Wang YV, WahlGM (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20:299-309.
10. Joerger AC, Fersht AR (2010) The tumor suppressor p53: From structures to drug discovery. Cold Spring Harbor Perspect Biol 2:a000919.
11. Vassilev LT, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848. (Pubitemid 38174664)
12. Tovar C, et al. (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc Natl Acad Sci USA 103:1888-1893. (Pubitemid 43228788)
13. Shangary S, Wang S (2008) Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 14:5318-5324.
14. Vassilev LT (2007) MDM2 inhibitors for cancer therapy. Trends Mol Med 13:23-31.
15. Ding K, et al. (2005) Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc 127:10130-10131. (Pubitemid 41045454)
16. Ding K, et al. (2006) Structure-based design of spiro-oxindoles as potent, specific smallmolecule inhibitors of the MDM2-p53 interaction. J Med Chem 49:3432- 3435.
17. Popowicz GM, Domling A, Holak TA (2011) The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl 50:2680-2688.
18. Wade M, Wahl GM (2009) Targeting Mdm2 and Mdmx in cancer therapy: Better living through medicinal chemistry? Mol Cancer Res 7:1-11.
19. Vogel SM, Bauer MR, Boeckler FM (2011) DEKOIS: Demanding evaluation kits for objective in silico screening - A versatile tool for benchmarking docking programs and scoring functions. J Chem Inf Model 51:2650-2665.
20. Hofmann AF (2004) Detoxification of lithocholic acid, a toxic bile acid: Relevance to drug hepatotoxicity. Drug Metab Rev 36:703-722.
21. Katona BW, Anant S, Covey DF, Stenson WF (2009) Characterization of enantiomeric bile acid-induced apoptosis in colon cancer cell lines. J Biol Chem 284:3354-3364.
22. Makishima M, et al. (2002) Vitamin D receptor as an intestinal bile acid sensor. Science 296:1313-1316. (Pubitemid 34522785)
23. Parks DJ, et al. (1999) Bile acids: Natural ligands for an orphan nuclear receptor. Science 284:1365-1368. (Pubitemid 29289664)
24. Kallen J, et al. (2009) Crystal structures of human MdmX (HdmX) in complex with p53 peptide analogues reveal surprising conformational changes. J Biol Chem 284:8812-8821.
25. Yu GW, Vaysburd M, Allen MD, Settanni G, Fersht AR (2009) Structure of human MDM4 N-terminal domain bound to a single-domain antibody. J Mol Biol 385:1578-1589.
26. Hartshorn MJ, et al. (2007) Diverse, high-quality test set for the validation of protein-ligand docking performance. J Med Chem 50:726-741. (Pubitemid 46332985)
27. Czarna A, et al. (2009) High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle 8:1176-1184.
28. Fersht AR (1999) Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding (W.H. Freeman, New York).
29. Teufel DP, Freund SM, Bycroft M, Fersht AR (2007) Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. Proc Natl Acad Sci USA 104:7009-7014. (Pubitemid 47186000)
30. Shangary S, et al. (2008) Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 105:3933-3938. (Pubitemid 351723502)
31. Laurie NA, et al. (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444:61-66. (Pubitemid 44684754)
32. Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screening 4:67-73. (Pubitemid 29278954)
33. Nikolovska-Coleska Z, et al. (2004) Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem 332:261-273. (Pubitemid 39485734)
34. Baell JB, Holloway GA (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719-2740.
35. Walters WP, Namchuk M (2003) Designing screens: How to make your hits a hit. Nat Rev Drug Discovery 2:259-266. (Pubitemid 37361684)
36. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727-748. (Pubitemid 27170693)
37. Verdonk ML, et al. (2005) Modeling water molecules in protein-ligand docking using GOLD. J Med Chem 48:6504- 6515.
38. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 11:425- 445.
39. Moitessier N, Englebienne P, Lee D, Lawandi J, Corbeil CR (2008) Towards the development of universal, fast and highly accurate docking/scoring methods: A long way to go. Br J Pharmacol 153(Suppl 1):S7-26.